Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease.
Georg SemmlerTeresa BinterKarin KozbialPhilipp SchwablStefanie Hametner-SchreilAlberto ZanettoSabrina GavassoDavid ChromyDavid Josef Maria BauerBenedikt SimbrunnerBernhard ScheinerTheresa A BucsicsAlbert F StättermayerMatthias PinterPetra Steindl-MundaRainer SchöflFrancesco Paolo RussoPaolo SimioniMichael TraunerPeter FerenciThomas ReibergerMattias MandorferPublished in: Hepatology (Baltimore, Md.) (2021)
FU-LSM/FU-VITRO are strongly and independently predictive of posttreatment hepatic decompensation in HCV-induced ACLD. An algorithm combining these noninvasive markers not only rules in or rules out FU-CSPH, but also identifies populations at negligible versus high risk for hepatic decompensation. FU-LSM/FU-VITRO are readily accessible and enable risk stratification after sustained virological response, and thus facilitate personalized management.